Temple University

The study will use NantHealth's GPS Cancer test to help treat adult and pediatric brain cancer patients.

Two recent studies confirm that CRISPR/Cas9 can edit and inhibit latent HIV provirus, but one of them hints that the virus can develop resistance to excision.

Researchers saw higher-than-anticipated genetic diversity when they sequenced a handful of Plasmodium vivax isolates from a malaria endemic region in Colombia.

The cancer genetic non-profit has opened a new facility located at Temple University.

In the first phase of the three-part pilot program, three projects will be chosen from 10 institutions in the Philadelphia region, Delaware, and New Jersey to receive one-year grants worth as much as $200,000 for proof-of-concept studies.

News Briefs

Premium

Cerenis, Montreal Heart Institute, UVA, Ortho Clinical, Mirna, UCSF, Case Western, Diagnostic Hybrids, iBridge Network, Ben Franklin Tech Partners, and more…

A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.

Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.

Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.

In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.